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Abstract:
Purpose: To identify patient-reported outcomes (PROs) and other clinical 
outcome measures (contrast sensitivity [CS], low-luminance visual 
acuity [LLVA] and reading acuity or reading speed [RA-RS]), relevant to 
patients with age-related macular degeneration (AMD) or diabetic 
retinopathy (DR), which would be recommended for use in clinical 
practice. 
Methods: The RAND/UCLA Appropriateness Method, based on the 
synthesis of the scientific evidence and the collective judgment of an 
expert panel using the two-round Delphi method, was applied. The 
evidence synthesis was performed by searching for articles on outcome 
measures for AMD and/or DR published between 2005 and 2018 in 
English or Spanish. The expert panel consisted of 14 Spanish 
ophthalmologists, who rated the recommendation degree for each 
outcome measure on a scale of 1 (extremely irrelevant) to 9 (maximum 
relevance). The recommended outcome measures were established 
according to the panel median score and the level of the panelists’ 
agreement. 
Results: Through the evidence search, 33 PRO-specific questionnaires 
(21 for visual function, 6 for AMD, 3 for DR, 1 for AMD and DR) and 2 
treatment satisfaction questionnaires (one on AMD and one on DR) were 
identified. In addition, 21 methods were found for measuring CS, 5 for 
LLVA, and 9 for RA-RS. According to the panel ratings, 11 of the 64 
outcome measures evaluated for AMD, and 7 of the 61 evaluated for DR 
were recommended. 
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Conclusions: The AMD and DR outcome measures recommended will 
help ophthalmologists choose the outcome measure most appropriate for 
their patients. Furthermore, the use of PROs will contribute to shifting 
clinical practice towards patient-centered medicine.
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TITLE: Beyond Visual Acuity: Patient-relevant Assessment Measures of Visual 
Function in Retinal Diseases
ABSTRACT
Purpose: To identify patient-reported outcomes (PROs) and other clinical outcome 
measures (contrast sensitivity [CS], low-luminance visual acuity [LLVA] and reading 
acuity or reading speed [RA-RS]), relevant to patients with age-related macular 
degeneration (AMD) or diabetic retinopathy (DR), which would be recommended for 
use in clinical practice.
Methods: The RAND/UCLA Appropriateness Method, based on the synthesis of the 
scientific evidence and the collective judgment of an expert panel using the two-round 
Delphi method, was applied. The evidence synthesis was performed by searching for 
articles on outcome measures for AMD and/or DR published between 2005 and 2018 in 
English or Spanish. The expert panel consisted of 14 Spanish ophthalmologists, who 
rated the recommendation degree for each outcome measure on a scale of 1 (extremely 
irrelevant) to 9 (maximum relevance). The recommended outcome measures were 
established according to the panel median score and the level of the panelists’ 
agreement.
Results: Through the evidence search, 33 PRO-specific questionnaires (21 for visual 
function, 6 for AMD, 3 for DR, 1 for AMD and DR) and 2 treatment satisfaction 
questionnaires (one on AMD and one on D ) were identified. In addition, 21 methods 
were found for measuring CS, 5 for LLVA, and 9 for RA-RS. According to the panel 
ratings, 11 of the 64 outcome measures evaluated for AMD, and 7 of the 61 evaluated 
for DR were recommended.
Conclusions: The AMD and DR outcome measures recommended will help 
ophthalmologists choose the outcome measure most appropriate for their patients. 
Furthermore, the use of PROs will contribute to shifting clinical practice towards 
patient-centered medicine.
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Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are important 
retinal diseases. AMD produces central visual acuity (VA) loss, leading to severe and 
permanent vision impairment and blindness, with great impact on patients’ quality of 
life. It is estimated that in Europe, 3.3% of people over 65 suffer from AMD [1], and 
about 200 million worldwide [2]. DR is the main cause of preventable blindness in 
working-age people. The estimated prevalence of DR is 40% in patients with type 2 
diabetes and 86% in patients with type 1 diabetes [3].
Several objective measures can estimate the impairment degree in retinal pathologies, 
such as VA or optical coherence tomography (OCT), contrast sensitivity (CS), low-
luminance visual acuity (LLVA), or reading acuity or reading speed (RA-RS). 
However, these objective measures do not necessarily reflect accurately the impact of 
their vision loss on patients’ daily activities or quality of life. Therefore, instruments 
(questionnaires) known as Patient-reported outcomes (PROs) [4-6] have been 
developed, as well as methodology to ensure their scientific validity [6-10]. The PROs 
may be generic or specific [11]. Generic questionnaires measure health-related quality 
of life dimensions and may be applied to any type of patient or condition, e.g., the 
EuroQoL [12] or the 36-Item Short Form Health Survey (SF-36) [13]. Specific 
questionnaires may be disease-specific (e.g., cardiac failure, glaucoma, AMD), 
population-specific (e.g., frail elderly, blind), function-specific (e.g., sleep, visual 
function), or problem-specific (e.g., pain, dyspnea).
In ophthalmology, numerous PRO measures have been developed [14]. A 2013 review 
identified 121 PROs for vision-related diseases [15]. In 117 clinical trials published 
between 2010 and 2013 on AMD interventions, 38 of the 858 outcome variables used 
were PROs [16]. In a 2017 review on retinal diseases, 110 PROs were identified, of 
which 62 were generic, 19 were ophthalmic-specific (e.g., the National Eye Institute 
Visual Functioning Questionnaire [NEI-VFQ]), and 29 were retinal-specific (e.g., the 
Daily Living Tasks Dependent on Vision [DLTV] for AMD and the Retinopathy-
Dependent Quality of Life Questionnaire [RetDQoL] for DR) [17].
Given the plethora of PROs, the aim of this study is to identify PROs and other outcome 
measures (CS, LLVA, RA-RS) relevant to AMD or DR patients that could be 
recommended for use in clinical practice in Spain.
METHODS
The RAND/UCLA Appropriateness Method (RUAM) [18,19] was used to address the 
project aim. The RUAM is based on a synthesis of the scientific evidence and the 
collective judgment of an expert panel using the two-round Delphi method. With the 
RUAM, appropriateness criteria have been developed for numerous diagnostic and 
therapeutic procedures in different specialties [20-25], including ophthalmology [26-
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28]. There is sufficient evidence regarding the sound methodology and the RUAM 
predictive validity on patient outcomes [22,29-35].
To apply the RUAM these steps were followed: 1) constitution of the expert panel; 2) 
creation of outcome measures list; 3) creation the first Delphi round questionnaire; 4) 
first Delphi round; 5) first round analysis and preparation of the second round 
questionnaires; 6) second Delphi round; and 7) second round analysis and proposal of 
the outcome measures to be recommended.
To assure the panel heterogeneity, the project Scientific Committee (SC) 
established the following criteria for the panel constitution: 1) Geography: 
regional distribution as ample as possible, 2) Experience: <10 years (2 panelists), 
10-25 years (10 panelists), > 25 years (3 panelists); 3) Scientific production : At 
least 5 panelists with any publication on AMD or DR in the last 10 years; and 4) 
Gender: At least 5 panelist of each gender. 
The SC proposed a list of 40 candidates, of which 15 were selected in such a way 
that would meet the desired distribution. Finally, the panel distribution was: 
gender (8 females, 7 males), location (from 8 Spanish regions), experience (<10, 10-
25, and >25 years: 2, 10, and 3 panelists respectively), and scientific publications on 
AMD and/or DR in the past 10 years (7 had at least one publication). The method 
requires that each panelist must not know who the other panelists are.
To create the list of outcome measures for visual function, an evidence synthesis was 
performed (Annex 1). The bibliographic search was done on articles published from 
2005 through 2018, in English or Spanish, using the Medline, Spanish Medical Index 
(IME), and Medicina en Español (MEDES) bibliography databases. Additionally, the 
bibliography of the last systematic review on the subject [17] was manually reviewed.
Thirty-three PRO questionnaires were identified in the evidence search, of which 21 
were specific to visual function (e.g., NEI-VFQ-25), 6 to AMD (e.g., Macular Disease 
Dependent Quality of Life Questionnaire [MacDQoL]), 3 to DR (e.g., Retinopathy-
Dependent Quality of Life questionnaire [RetDQoL]), 1 to AMD and DR (Low-
Luminance Questionnaire (LLQ)), 1 to AMD treatment satisfaction (MacTSQ), and 1 to 
DR treatment satisfaction (RetTSQ).
Twenty-one methods were identified to measure CS; the most used was the Pelli-
Robson, followed by the Optec-Functional Vision Analyzer (Optec-FVA). Five methods 
were identified to measure LLVA (Electronic Visual Acuity tester, Early Treatment 
Diabetic Retinopathy Study (ETDRS), Smith-Kettlewell Low-Luminance Acuity Test 
(SKILL), Bailey-Lovie charts, and Snellen lines). Of the 8 methods found to measure 
RA-RS, the most used was the Minnesota Low-Vision Reading Test (MNRead), 
followed by the Radner and the method used in the Submacular Surgery Trials (SST).
Finally, the list included 125 outcome measures, 64 for AMD and 61 for DR.
Page 4 of 113
https://mc.manuscriptcentral.com/ej-ophthalmology































































The evidence synthesis, the articles describing the PROs questionnaires and the 
first Delphi round questionnaire were sent to the panelists. They rated each of the 
125 outcome measures using a scale of 1 to 9, where 1 means “extremely 
irrelevant” and 9 “maximum relevance” for use in Spain. Relevance was defined as 
the importance of each outcome measure in clinical practice for early diagnosis 
and outcomes follow-up. Ratings were received from 14 panelists (one panelist was 
unable to participate).
The panel’s ratings were analyzed, and individualized questionnaires were created for 
each panelist for the second Delphi round. In this questionnaire, each panelist was able 
to see her/his own first round responses and the distribution of the other panelists’ 
ratings with anonymized individual scores. With this anonymous feedback process, 
each panelist rated all the items, even if her/his score was the same as in the first round. 
All 14 panelists responded.
Establishing the recommended outcome measures
In the second-round panel ratings, since the number of panelists was not a multiple of 3, 
the IPRAS method (Interpercentile Range Adjusted for Symmetry) [18] was used to 
assess the level of agreement among the panelists. The disagreement measured with the 
IPRAS method gives a mathematical result equivalent to that which would occur in a 
panel multiple of three if, at least, a third of the panelists had scored in the range 1-3, 
and at least a third had scored in the range 7-9. As a result, the relevance of using each 
outcome measure was classified as with agreement (+) or disagreement (-).
The outcome measures with a median rating <4 with agreement were classified as “not 
recommended” (NR), and those with a median rating ≥7 with agreement were classified 
as “recommended” (RE). The category “may be recommended” (MR) was given to the 
rest: all those with a median ≥ 4 and <7, and to all those rated with disagreement, 
regardless of the median.
RESULTS
Table 1 shows the outcome measure in the left column. The columns labeled AMD and 
DR show the panel ratings median “M.” Column “A” (Agreement) shows the agreement 
(+) or disagreement (-) among the panel ratings. The column labeled “R” 
(Recommendation) indicates the three recommendation categories: RE, MR, and NR. 
Of the 29 PRO questionnaires for AMD, 24 were rated with agreement and 5 with 
disagreement, resulting 8 RE, 10 MR and 11 NR. Of the 26 PRO questionnaires for DR, 
20 were rated with agreement and 6 with disagreement, resulting 4 RE, 9 MR, and 13 
NR (Table 1).
Twenty-one measures were identified for CS. For AMD, 20 were rated with agreement 
and 1 with disagreement, resulting 1 RE, 3 MR and 17 NR. For DR, all 21 were rated 
with agreement, resulting 1 RE, 2 MR and 18 NR (Table 2).
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Five outcome measures were identified for LLVA. For AMD, 3 were rated with 
agreement and 2 with disagreement, resulting in 1 RE, 3 MR and 1 NR. For DR, 4 were 
rated with agreement and 1 with disagreement, resulting in 1 RE, 3 MR and 1 NR 
(Table 3).
Eight outcome measures were identified for RA-RS. Both for AMD and for DR, all 8 
were rated with agreement, resulting 1 RE, 2 MR and 5 NR for both pathologies (Table 
4).
Recommended outcome measures
The 11 outcome measures recommended for AMD and the 7 recommended for DR are 
shown in Table 5. By definition, all the recommended measures were rated with 
agreement. In the case of visual function PROs, the recommended measures have been 
listed according to the median value.
DISCUSSION
In clinical practice, health professionals face the challenge of classifying the patient’s 
state or measuring the outcomes of an intervention. To that end, there are objective 
measures such as VA, perimetry, and OCT, as well as PROs, which capture the 
patient’s experience, preference, or perception [4-6]. Thirty-three PRO questionnaires 
identified focused on AMD and DR (Annex 1). The PRO questionnaires differ in the 
areas they explore, the items they include and the way they are administered (e.g., self-
administered, interviews, …), so they may present different complexities and require 
different resources (e.g., time, trained staff, …). A PRO that may be applicable in one 
clinical context might not be applicable in another.
The methodology is a key factor in projects to develop clinical practice 
recommendations. In this case, we used the RUAM, rather than a simple Delphi 
method, because the RUAM adds the robustness of the evidence synthesis. The RUAM 
was initially developed to make recommendations about the appropriateness of medical 
procedures [18,24]. A debated issue surrounding RUAM is the interpretation of 
indications rated as “uncertain,” which in recent studies was renamed “may be 
appropriate” [36] and which, in this study, we named “may be recommended.” When an 
outcome measure has been classified as MR with agreement, we interpret that the 
advantages and disadvantages of using the outcome measure are similar. When the MR 
category has been assigned with disagreement, it must be interpreted individually, as 
some panelists might have rated that outcome measure for use in a high-level hospital, 
and other panelists might have been thinking of hospitals with fewer resources. This 
classification offers the flexibility of using measures rated MR in some centers, 
depending on their specific characteristics.
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Interestingly, only 11 outcome measures for AMD and seven for DR were deemed 
recommended. This might help ophthalmologists since they may focus on the 
recommendations instead of evaluating all other available outcome measures. Other 
studies have identified relevant outcome measures for AMD patients using the Delphi 
method, but they did not focus on PROs [37-39]. The only PRO recommended in one of 
the studies [37] was the Impact of Vision Impairment Questionnaire (IVI), which is also 
recommended in our study.
The RUAM, like all methods, has limitations, such as the potencial familiarity bias. 
A test less known could be scored poorer than other more familiar that might 
result with a good score. For example, the panel ranked the ETDRS chart, a test 
that was design following the principles of Bailey-Lovie, better than the Bailey-
Lovie chart itself. For this reason, to try to avoid this bias, the panel members have 
a variety of professional profiles in terms of gender, experience, geographic 
distribution and scientific production, in addition, the panelists were provided with 
the articles describing the PROs questionnaires. In any case, evidence exists on the 
method’s validity in procedures of several specialties [29-35,40], including 
Ophthalmology [27,28]. The RUAM has shown that clinical outcomes are better when 
patients receive an appropriate procedure or when an inappropriate procedure is not 
performed [22,28].
Although the panelists rated each outcome measure’s relevance within the context of 
Spanish Ophthalmology services, we believe the recommendations may be applicable in 
other contexts given the similarity in structure and process of Ophthalmology services 
in other healthcare systems.
In summary, we believe that the AMD and DR outcome measures recommended in this 
study will help ophthalmologists choose the most appropriate of the existing outcome 
measures for managing their patients. Furthermore, the use of PROs will contribute to 
shifting clinical practice towards patient-centered medicine.
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Table 1. AMD and DR patient-reported outcome measures
Patient-reported outcome measure AMD DR
Visual function-specific: M A R M A R
Activity Inventory (AI) 3.0 + NR 2.0 + NR
Adaptation to Vision Loss Scale (AVL) 2.0 + NR 1.5 + NR
Daily Living Tasks Dependent on Vision (DLTV) 7.0 + RE 2.0 + NR
DLTV-11 5.0 - MR 1.5 + NR
Extended Mainz Questionnaire (EMQ) 2.5 + NR 1.0 + NR
Impact of Vision Impairment Questionnaire (IVI) 7.5 + RE 7.0 + RE
Low Vision Quality of Life Questionnaire (LVQOL) 7.0 + RE 4.5 - MR
Melbourne Low Vision Index (MLVI) 3.0 + NR 1.0 + NR
Manchester Low Vision Questionnaire (MLVQ) 2.0 + NR 1.0 + NR
National Eye Institute Visual Function Questionnaire-8 (NEI-VFQ-8) 4.5 - MR 3.5 - MR
NEI-VFQ-9 4.0 - MR 3.0 - MR
NEI-VFQ-17 2.5 - MR 2.5 + NR
NEI-VFQ-25 9.0 + RE 9.0 + RE
NEI-VFQ-39 7.0 + RE 2.0 - MR
NEI-VFQ-51 3.0 + NR 2.5 + NR
Visual Function Index (11 ítems) (VF-11) 5.5 - MR 5.0 - MR
VF-14 4.5 + MR 5.0 + MR
VF-4D 2.0 + NR 1.0 + NR
Visual Function Questionnaire Utility Index (VFQUI) 2.0 + NR 2.0 + NR
Vision and Quality of Life Index (VisQoL) 2.5 + NR 2.5 + NR
Vision Preference Value Scale (VPVS) 1.5 + NR 1.5 + NR
AMD-specific: M A R
Activity Limitation Questionnaire (ALQ) 4.5 + MR
AMD Health and Impact Questionnaire (AMD-HIQ) 3.0 + NR
AMD Self-Efficacy Questionnaire (AMD-SEQ) 4.0 + MR
Functional Reading Independence (FRI) 4.0 + MR
Macular disease Dependent Quality of Life questionnaire (MacDQoL) 7.0 + RE
Night Vision Questionnaire 10-item (NVQ-10) 4.0 + MR
DR-specific: M A R
Quality of Life Item Banks (QoL-IB) 4.5 - MR
Retinopathy-Dependent Quality of Life questionnaire (RetDQoL) 7.0 + R
Vision-Related Functional Burden (VRFB) 5.0 + MR
AMD and DR-specific: M A R M A R
Low-luminance questionnaire (LLQ) 7.0 + R 6.0 + MR
Treatment Satisfaction-specific: M A R M A R
Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) 7.0 + R
Retinopathy treatment satisfaction questionnaire (RetTSQ) 7.0 + R
AMD: Age-related macular degeneration; DR: Diabetic retinopathy; M: Median; A: Agreement level 
("+": Agreement; "-": Disagreement.); R: Recommendation; RE: Recommended; MR: May Be 
Recommended; NR: Not recommended.
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Table 2. Contrast sensitivity tests for AMD and DR
AMD DR
Contrast sensitivity test M A R M A R
Cambridge low-contrast grating system 2.0 + NR 3.0 + NR
Contrast Glare Test (CGT) 2.5 + NR 3.0 + NR
Contraste de luminancia de escenas 2.0 + NR 2.0 + NR
ChromaTest 2.0 + NR 2.0 + NR
CSV-1000 5.5 + MR 4.0 + MR
Functional Acuity Contrast Test (FACT) 4.0 + MR 3.5 + NR
Innova Systems 2.0 + NR 1.5 + NR
Lea Numbers low contrast number test 1.5 + NR 1.0 + NR
Mars Letter Contrast Sensitivity Test 2.5 + NR 1.5 + NR
Maximum color contrast sensitivity test (MCCS) 2.5 + NR 2.5 + NR
Melbourne Edge Test (MET) 2.0 + NR 2.5 + NR
Macular Multi-Function Assessment (MMFA) 1.5 + NR 1.5 + NR
M&S Technologies Smart System (MSTSS) 1.0 + NR 1.0 + NR
Optec-Functional Vision Analyzer (Optec-FVA) 5.0 - MR 5.0 + MR
Pelli-Robson 9.0 + RE 8.5 + RE
QUEST 1.5 + NR 1.5 + NR
Quick contrast sensitivity function 2.5 + NR 3.0 + NR
Spaeth/Richman Contrast Sensitivity test (SPARCS) 2.0 + NR 1.5 + NR
Test 2000 PRO 2.0 + NR 1.0 + NR
Visual Capacity Analyzer (VCA) 1.0 + NR 1.0 + NR
Vistech 2.5 + NR 3.0 + NR
AMD: Age-related macular degeneration; DR: Diabetic retinopathy; M: Median; A: Agreement level 
("+": Agreement; "-": Disagreement.); R: Recommendation; RE: Recommended; MR: May Be 
Recommended; NR: Not recommended.
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Table 3. Low luminance visual acuity tests for AMD and DR.
AMD DR
Low luminance visual acuity tests: M A R M A R
Bailey-Lovie 6.0 - MR 5.0 - MR
Electronic Visual Acuity tester 5.5 - MR 5.0 + MR
Early Treatment Diabetic Retinopathy Study (ETDRS) 8.0 + RE 7.0 + RE
Smith-Kettlewell low-luminance acuity test (SKILL) 4.5 + MR 4.5 + MR
Consecutive Snellen lines 3.0 + NR 3.0 + NR
AMD: Age-related macular degeneration; DR: Diabetic retinopathy; M: Median; A: Agreement level 
("+": Agreement; "-": Disagreement.); R: Recommendation; RE: Recommended; MR: May Be 
Recommended; NR: Not recommended.
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Table 4. Acuity/Speed Reading tests for AMD and DR.
AMD DR
Acuity/Speed Reading tests: M A R M A R
Modified Bailey-Lovie 2.5 + NR 2.5 + NR
Belfast Reading Index 1.0 + NR 1.0 + NR
International Reading Speed Texts (IReST) 4.5 + MR 4.0 + MR
Minnesota Low-Vision Reading Test (MNRead) 7.0 + RE 7.0 + RE
Pepper Visual Skills for Reading Test 1.5 + NR 2.0 + NR
Radner 5.0 + MR 4.0 + MR
Reading Explorer test (REX) 2.5 + NR 2.5 + NR
Submacular Surgery Trials (SST) 3.0 + NR 2.5 + NR
AMD: Age-related macular degeneration; DR: Diabetic retinopathy; M: Median; A: Agreement level 
("+": Agreement; "-": Disagreement.); R: Recommendation; RE: Recommended; MR: May Be 
Recommended; NR: Not recommended.
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Table 5. Recommended outcome measures for AMD and DR.
Outcome measure AMD DR
PROM specific of visual function: M M
NEI-VFQ-25 9.0 9.0
Impact of Vision Impairment Questionnaire (IVI) 7.5 7.0
Daily Living Tasks Dependent on Vision (DLTV) 7.0 -
Low Vision Quality of Life Questionnaire (LVQOL) 7.0 -
NEI-VFQ-39 7.0 -
PROM specific of AMD: M M
Macular disease Dependent Quality of Life questionnaire (MacDQoL) 7.0
PROM specific of DR: M M
Retinopathy-Dependent Quality of Life questionnaire (RetDQoL) 7.0
PROM specific of AMD and DR: M M
Low-luminance questionnaire (LLQ) 7.0 -
Specific for Treatment Satisfaction: M M
Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) 7.0
Retinopathy treatment satisfaction questionnaire (RetTSQ) 7.0
Contrast sensitivity test: M M
Pelli-Robson 9.0 8.5
Low luminance visual acuity test: M M
Early Treatment Diabetic Retinopathy Study (ETDRS) 8.0 7.0
Acuity/Speed Reading tests: M M
Minnesota Low-Vision Reading Test (MNRead) 7.0 7.0
AMD: Age-related macular degeneration; DR: Diabetic retinopathy; PROM: Patient-reported 
outcome measure; M: Median.
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